Eosinophil may be a predictor of immune-related adverse events induced by different immune checkpoint inhibitor types: A retrospective multidisciplinary study.
Yoshihiko TasakiYosuke SugiyamaShuzo HamamotoTaku NaikiTakehiro UmemuraKeisuke YokotaDaisuke KawakitaMotoki NakamuraRyo OgawaTakaya ShimuraYoshihisa MimuraYuji HottaKunihiro OdagiriNanami ItoMoeko IidaYuka KimuraHirokazu KomatsuHiromi KataokaShuji TakiguchiAkimichi MoritaShinichi IwasakiKatsuhiro OkudaAkio NiimiTakahiro YasuiYoko Furukawa-HibiPublished in: Cancer medicine (2023)
An increased eosinophil before the two-course treatment may be a predictor of irAEs in various cancers treated with different ICIs.